Genscript Biotech
Genscript Biotech Corporation, commonly referred to as Genscript, is a leading biotechnology company headquartered in the United States. Founded in 2002, Genscript has established itself as a pioneer in the fields of gene synthesis, peptide synthesis, and antibody development, serving a diverse range of industries including pharmaceuticals, academia, and diagnostics. With major operational regions across North America, Europe, and Asia, Genscript offers a comprehensive suite of services that includes custom gene and protein production, CRISPR gene editing, and molecular biology tools. The company is renowned for its innovative approach and high-quality products, which have positioned it as a trusted partner in the global biotech landscape. Genscript's commitment to advancing scientific research has led to numerous accolades, solidifying its reputation as a key player in the biotechnology sector.
DitchCarbon Score
How does Genscript Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genscript Biotech's score of 34 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genscript Biotech's reported carbon emissions
In 2024, GenScript Biotech reported total carbon emissions of approximately 39,376,800 kg CO2e for Scope 1, about 114,034,820 kg CO2e for Scope 2 (market-based), and around 387,589,810 kg CO2e for Scope 3 emissions. The combined total for Scope 1 and Scope 2 emissions (market-based) was approximately 153,411,610 kg CO2e. In 2023, the company recorded emissions of about 48,821,780 kg CO2e for Scope 1, 83,758,360 kg CO2e for Scope 2 (market-based), and approximately 314,658,760 kg CO2e for Scope 3, resulting in a total of about 132,580,140 kg CO2e for Scope 1 and Scope 2 combined (market-based). Despite these figures, GenScript Biotech has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company does not appear to inherit emissions data from a parent organisation, and all reported data is directly from GenScript Corporation. Overall, while GenScript Biotech has substantial emissions across all scopes, it currently lacks defined climate commitments or reduction strategies to address its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 48,821,780 | 00,000,000 |
| Scope 2 | 83,758,360 | 000,000,000 |
| Scope 3 | 314,658,760 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genscript Biotech is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
